flow trial semaglutide renal outcomes 2024 The drug everyone calls a weight-loss shot is also a kidney drug. Most patients on it have never been told the second half. In May 2024, the published in the FLOW clinical Trial (funded by

Patients reported no hypoglycemia, no significant weight fluctuations, and a similar incidence of gastrointestinal (GI)-related adverse effects

KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease

GLP-1 drugs like Ozempic could potentially be used to treat and slow the progression of Alzheimers disease, according to a new study presented in July at the Alzheimers Association International Conference in Philadelphia

Here's how to get started: Print the grocery list and shop this weekend Set aside 1-2 hours Sunday for basic meal prep (or use the hybrid approach) Stock your freezer with convenient backup options like Clean Eatz Kitchen meals Track your protein intake for the first week to ensure you're hitting targets Adjust portions based on your appetite and tolerance Want deeper guidance

Semaglutide and Tirzepatide are originally developed to manage type 2 diabetes

Contact your healthcare provider promptly if: Back pain persists beyond 23 weeks despite conservative measures Pain progressively worsens rather than improving Pain significantly interferes with daily activities or sleep Systemic symptoms develop (fever, night sweats) or unintentional weight loss beyond therapy goals Pain occurs in patients with cancer history or other risk factors for metastatic disease Flank pain accompanied by urinary symptoms (possible kidney stones or infection) Clinicians should obtain a thorough history, perform physical examination, and consider laboratory evaluation (including serum lipase and liver function tests) when indicated